As of November 9, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Monte Rosa Therapeutics, Inc. The largest reported stake is T. Rowe Price Associates, Inc.'s, at 10.5%. 20 filings are on record since August 14, 2025 (Schedule 13G/A, July 8, 2026).
Sell to companies like Monte Rosa Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 4,600,000 · Sole dispositive: 0 · Shared dispositive: 4,600,000 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Montanova Capital, LLC · Sole voting: 0 · Shared voting: 3,549,539 · Sole dispositive: 0 · Shared dispositive: 3,549,539 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 8,856,521 · Shared voting: 0 · Sole dispositive: 8,861,282 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-08
- · Reporting person: New Enterprise Associates 17, L.P. · Sole voting: 0 · Shared voting: 6,692,298 · Sole dispositive: 0 · Shared dispositive: 6,692,298 · SCHEDULE 13D/A, 2026-07-06
- · Holder: Bvf Partners L P · Percent: 6.3% · SCHEDULE 13G/A
Monte Rosa Therapeutics, Inc. has 20 Schedule 13D or 13G filings on record since 2025-08-14. 7 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 10.5% | 8,861,282 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
| Baker Bros. Advisors LP | 9.99% | 8,876,346 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 8.1% | 6,513,765 | SCHEDULE 13G/A, 2026-04-22 | 2026-03-31 | |
| New Enterprise Associates 17, L.P. | 7.9% | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 | 2026-07-01 |
| Bvf Partners L P | 6.3% | 5,085,886 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 5.5% | 4,622,151 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 | |
| Vestal Point Capital, LP | 5.4% | 4,600,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 4.83% | 2,988,953 | SCHEDULE 13G/A, 2025-10-31 | 2025-09-30 |
| Montanova Capital, LLC | 4.2% | 3,549,539 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Versant Venture Capital VI, L.P. | 3.4% | 2,236,708 | SCHEDULE 13D/A, 2026-01-09 | 2026-01-07 |
| Avoro Capital Advisors LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Monte Rosa Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Monte Rosa Therapeutics, Inc. and the records around it.
Monte Rosa Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), LENZ Therapeutics, Inc. (Nov 2025), LAVA Therapeutics N.V. (Sep 2025)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026), SpyGlass Pharma, Inc. (Feb 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Watch Monte Rosa Therapeutics, Inc.
Get an email when Monte Rosa Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Monte Rosa Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Monte Rosa Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monte Rosa Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8,856,521 | 0 | 8,861,282 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| New Enterprise Associates 17, L.P. | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| NEA Partners 17, L.P. | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| Nea 17 Gp, LLC | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| Anthony A. Florence, Jr. | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| Mohamad H. Makhzoumi | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| Scott D. Sandell | 0 | 6,692,298 | 0 | 6,692,298 | SCHEDULE 13D/A, 2026-07-06 |
| Forest Baskett | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Ali Behbahani | 135,432 | 0 | 135,432 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Carmen Chang | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Edward T. Mathers | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Paul Walker | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Rick Yang | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-07-06 |
| Vestal Point Capital, LP | 0 | 4,600,000 | 0 | 4,600,000 | SCHEDULE 13G, 2026-08-14 |
| Ryan Wilder | 0 | 4,600,000 | 0 | 4,600,000 | SCHEDULE 13G, 2026-08-14 |
| Montanova Capital, LLC | 0 | 3,549,539 | 0 | 3,549,539 | SCHEDULE 13G/A, 2026-08-14 |
| Averill Master Fund, Ltd. | 0 | 3,215,486 | 0 | 3,215,486 | SCHEDULE 13G/A, 2026-08-14 |
| Aaron Cowen | 0 | 3,549,539 | 0 | 3,549,539 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Monte Rosa Therapeutics, Inc. by CUSIP 61225M102 and gives its principal executive office as 321 HARRISON AVENUE, SUITE 900, BOSTON, MA 02118 (SCHEDULE 13G, 2026-08-14).
Source of funds (Item 3)
Not applicable.New Enterprise Associates 17, L.P., SCHEDULE 13D/A, 2026-07-06
Purpose of Transaction (Item 4)
New Enterprise Associates 17, L.P.
The information provided in Item 5(c) is hereby incorporated by reference. Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-07-06
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Avoro Capital Advisors LLC | 6.1% | SCHEDULE 13G/A |
| 2025-10-03 | Adam Goulburn | 7.7% | SCHEDULE 13G |
| 2025-10-17 | Chen Yu | 7.2% | SCHEDULE 13G |
| 2025-10-31 | The Vanguard Group | 4.83% | SCHEDULE 13G/A |
| 2025-11-12 | Versant Venture Capital VI, L.P. | 5.1% | SCHEDULE 13D/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 7.5% | SCHEDULE 13G/A |
| 2025-11-14 | Avoro Capital Advisors LLC | 0% | SCHEDULE 13G/A |
| 2026-01-09 | Versant Venture Capital VI, L.P. | 3.4% | SCHEDULE 13D/A |
| 2026-01-21 | Adam Goulburn | 8.7% | SCHEDULE 13G/A |
| 2026-02-17 | Bvf Partners L P | 5.9% | SCHEDULE 13G/A |
| 2026-02-17 | Baker Bros. Advisors LP | 6.7% | SCHEDULE 13G/A |
| 2026-03-19 | New Enterprise Associates 17, L.P. | 9.7% | SCHEDULE 13D/A |
| 2026-04-22 | Adam Goulburn | 8.1% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 6.3% | SCHEDULE 13G/A |
| 2026-05-15 | Baker Bros. Advisors LP | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Chen Yu | 5.5% | SCHEDULE 13G/A |
| 2026-07-06 | New Enterprise Associates 17, L.P. | 7.9% | SCHEDULE 13D/A |
| 2026-07-08 | T. Rowe Price Associates, Inc. | 10.5% | SCHEDULE 13G/A |
| 2026-08-14 | Vestal Point Capital, LP | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Montanova Capital, LLC | 4.2% | SCHEDULE 13G/A |
Questions about who owns Monte Rosa Therapeutics, Inc.
Who owns Monte Rosa Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Monte Rosa Therapeutics, Inc.: T. Rowe Price Associates, Inc. (10.5%, Schedule 13G/A, filed 2026-07-08), Baker Bros. Advisors LP (9.99%, Schedule 13G/A, filed 2026-05-15), Adam Goulburn (8.1%, Schedule 13G/A, filed 2026-04-22), New Enterprise Associates 17, L.P. (7.9%, Schedule 13D/A, filed 2026-07-06) and Bvf Partners L P (6.3%, Schedule 13G/A, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Monte Rosa Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Monte Rosa Therapeutics, Inc. on this page are T. Rowe Price Associates, Inc. (10.5%), Baker Bros. Advisors LP (9.99%) and Adam Goulburn (8.1%).
When did T. Rowe Price Associates, Inc. buy into Monte Rosa Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Associates, Inc. on this page is the Schedule 13G/A, filed 2025-11-14, reporting 7.5%; its latest, Schedule 13G/A filed 2026-07-08, reports 10.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Monte Rosa Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.